These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23873346)

  • 1. The gut-liver axis.
    Visschers RG; Luyer MD; Schaap FG; Olde Damink SW; Soeters PB
    Curr Opin Clin Nutr Metab Care; 2013 Sep; 16(5):576-81. PubMed ID: 23873346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanism of gut-microbiota-liver axis in the pathogenesis of intestinal failure-associated liver disease].
    Fan SX; Wang J; Li Q; Li YS; Guan WX; Li JS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jan; 24(1):94-100. PubMed ID: 33461259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prebiotic effects: metabolic and health benefits.
    Roberfroid M; Gibson GR; Hoyles L; McCartney AL; Rastall R; Rowland I; Wolvers D; Watzl B; Szajewska H; Stahl B; Guarner F; Respondek F; Whelan K; Coxam V; Davicco MJ; Léotoing L; Wittrant Y; Delzenne NM; Cani PD; Neyrinck AM; Meheust A
    Br J Nutr; 2010 Aug; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing parenteral nutrition liver disease.
    Kelly DA
    Early Hum Dev; 2010 Nov; 86(11):683-7. PubMed ID: 20923719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice.
    Degirolamo C; Rainaldi S; Bovenga F; Murzilli S; Moschetta A
    Cell Rep; 2014 Apr; 7(1):12-8. PubMed ID: 24656817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunomodulatory role of bile acids.
    Sipka S; Bruckner G
    Int Arch Allergy Immunol; 2014; 165(1):1-8. PubMed ID: 25277277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Parenteral Nutrition-Associated Liver and Gut Injury.
    Madnawat H; Welu AL; Gilbert EJ; Taylor DB; Jain S; Manithody C; Blomenkamp K; Jain AK
    Nutr Clin Pract; 2020 Feb; 35(1):63-71. PubMed ID: 31872510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
    Delarue J; Lallès JP
    Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of bowel permeability.
    Soeters PB; Luyer MD; Greve JW; Buurman WA
    Curr Opin Clin Nutr Metab Care; 2007 Sep; 10(5):632-8. PubMed ID: 17693749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Let there be bile"--understanding hepatic injury in cholestasis.
    Sokol RJ; Devereaux M; Dahl R; Gumpricht E
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S4-9. PubMed ID: 16819400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut permeability, its interaction with gut microflora and effects on metabolic health are mediated by the lymphatics system, liver and bile acid.
    Tran CD; Grice DM; Wade B; Kerr CA; Bauer DC; Li D; Hannan GN
    Future Microbiol; 2015; 10(8):1339-53. PubMed ID: 26234760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.
    van Best N; Jansen PL; Rensen SS
    Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo degradation of cholesterol to bile acids is reduced in patients receiving parenteral nutrition.
    Carulli L; Del Puppo M; Anzivino C; Zambianchi L; Gabbi C; Baldelli E; Odoardi MR; Loria P; Carulli N; Bertolotti M
    JPEN J Parenter Enteral Nutr; 2014 Feb; 38(2):220-6. PubMed ID: 23426743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease.
    Compare D; Coccoli P; Rocco A; Nardone OM; De Maria S; Cartenì M; Nardone G
    Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):471-6. PubMed ID: 22546554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
    Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
    Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal Failure-Associated Liver Disease.
    Pironi L; Sasdelli AS
    Clin Liver Dis; 2019 May; 23(2):279-291. PubMed ID: 30947877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: The function and regulation of proteins involved in bile salt biosynthesis and transport.
    Pellicoro A; Faber KN
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():149-60. PubMed ID: 18081658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
    Scorletti E; Byrne CD
    Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gut microbiota and the metabolic health of the host.
    Joyce SA; Gahan CG
    Curr Opin Gastroenterol; 2014 Mar; 30(2):120-7. PubMed ID: 24468803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.